|
AU736993B2
(en)
*
|
1997-01-16 |
2001-08-09 |
Novo Nordisk A/S |
Practical in vitro sialylation of recombinant glycoproteins
|
|
US6689604B1
(en)
|
1998-03-20 |
2004-02-10 |
National Research Council Of Canada |
Lipopolysaccharide α-2,3 sialyltransferase of Campylobacter jejuni and its uses
|
|
PT1137789E
(pt)
|
1998-12-09 |
2010-10-21 |
Phyton Holdings Llc |
Um método para produzir glicoproteínas possuindo glicosilação de tipo humano
|
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
|
ATE365219T1
(de)
|
1999-10-26 |
2007-07-15 |
Plant Res Int Bv |
Glykolisierung des säugetiertyps in pflanzen
|
|
NZ522320A
(en)
*
|
2000-05-12 |
2007-03-30 |
Neose Technologies Inc |
In vitro modification of glycosylation patterns of recombinant glycopeptides
|
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
|
CN100385006C
(zh)
|
2001-01-19 |
2008-04-30 |
陶氏化学公司 |
利用植物细胞分泌性生产具有人型糖链的糖蛋白的方法
|
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
|
EP2292273A3
(en)
|
2001-10-10 |
2011-11-23 |
BioGeneriX AG |
Remodeling and glycoconjugation of peptides
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
|
US7399613B2
(en)
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
IL161235A0
(en)
*
|
2001-10-22 |
2004-09-27 |
Applied Research Systems |
Fsh composition, its preparation and use
|
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
|
JP2005535280A
(ja)
|
2001-11-28 |
2005-11-24 |
ネオーズ テクノロジーズ， インコーポレイテッド |
エンドグリカナーゼを用いる糖タンパク質のリモデリング
|
|
CA2478294C
(en)
|
2002-03-19 |
2013-09-03 |
Plant Research International B.V. |
Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
|
|
CA2923247A1
(en)
|
2002-03-19 |
2003-09-25 |
Stichting Dienst Landbouwkundig Onderzoek |
Optimizing glycan processing in plants
|
|
ES2363205T3
(es)
|
2002-06-21 |
2011-07-26 |
Novo Nordisk Health Care Ag |
Glicoformas del factor vii pegilado.
|
|
DE60336555D1
(de)
|
2002-06-21 |
2011-05-12 |
Novo Nordisk Healthcare Ag |
Pegylierte glykoformen von faktor vii
|
|
MXPA05000063A
(es)
*
|
2002-07-01 |
2005-04-08 |
Kenneth S Warren Inst Inc |
Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
|
|
AU2003301332B2
(en)
*
|
2002-10-17 |
2008-06-12 |
Pharming Intellectual Property B.V. |
Protein modification
|
|
AR042145A1
(es)
|
2002-11-27 |
2005-06-08 |
Dow Agrociences Llc |
Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
|
|
AU2004221824B2
(en)
*
|
2003-03-14 |
2009-08-27 |
Ratiopharm Gmbh |
Branched water-soluble polymers and their conjugates
|
|
WO2004091499A2
(en)
*
|
2003-04-09 |
2004-10-28 |
Neose Technologies, Inc. |
Intracellular formation of peptide conjugates
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
CA2522345A1
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7932364B2
(en)
*
|
2003-05-09 |
2011-04-26 |
Novo Nordisk A/S |
Compositions and methods for the preparation of human growth hormone glycosylation mutants
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
CN1897959A
(zh)
*
|
2003-09-29 |
2007-01-17 |
沃伦药品公司 |
用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
|
|
NZ547168A
(en)
*
|
2003-11-24 |
2010-05-28 |
Biogenerix Ag |
Glycopegylated erythropoietin
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20080305992A1
(en)
*
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
|
NZ548123A
(en)
|
2004-01-08 |
2010-05-28 |
Novo Nordisk As |
O-linked glycosylation of peptides
|
|
AU2005208897B2
(en)
*
|
2004-01-26 |
2011-05-19 |
Ratiopharm Gmbh |
Branched polymeric sugars and nucleotides thereof
|
|
CA2565414A1
(en)
|
2004-05-04 |
2005-11-24 |
Novo Nordisk Health Care Ag |
O-linked glycoforms of polypeptides and method to manufacture them
|
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
|
WO2006020372A2
(en)
*
|
2004-07-23 |
2006-02-23 |
Neose Technologies, Inc. |
Enzymatic modification of glycopeptides
|
|
WO2006031811A2
(en)
|
2004-09-10 |
2006-03-23 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
|
JP4812625B2
(ja)
*
|
2004-10-18 |
2011-11-09 |
日本たばこ産業株式会社 |
糖転移酵素の酵素活性を向上させる方法
|
|
EP1814573B1
(en)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
EP1838332A1
(en)
*
|
2005-01-06 |
2007-10-03 |
Neose Technologies, Inc. |
Glycoconjugation using saccharyl fragments
|
|
CA2593682C
(en)
*
|
2005-01-10 |
2016-03-22 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
|
JP5235657B2
(ja)
*
|
2005-03-24 |
2013-07-10 |
バイオジェネリックス ゲーエムベーハー |
原核生物における可溶性活性真核生物グリコシルトランスフェラーゼの発現
|
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
US20110003744A1
(en)
*
|
2005-05-25 |
2011-01-06 |
Novo Nordisk A/S |
Glycopegylated Erythropoietin Formulations
|
|
WO2006127910A2
(en)
*
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin formulations
|
|
US20080255026A1
(en)
*
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
|
FI20055398A0
(fi)
|
2005-07-08 |
2005-07-08 |
Suomen Punainen Risti Veripalv |
Menetelmä solupopulaatioiden evaluoimiseksi
|
|
US20070105755A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
MX2008002395A
(es)
*
|
2005-08-19 |
2008-03-18 |
Neose Technologies Inc |
Factor vii y factor viia glicopegilados.
|
|
AU2006287224A1
(en)
*
|
2005-08-31 |
2007-03-08 |
Centocor, Inc. |
Host cell lines for production of antibody constant region with enhanced effector function
|
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
|
FR2901707B1
(fr)
*
|
2006-05-31 |
2017-09-29 |
Lab Francais Du Fractionnement |
Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
|
|
AR078117A1
(es)
|
2006-06-20 |
2011-10-19 |
Protech Pharma S A |
Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
|
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
FR2904558B1
(fr)
*
|
2006-08-01 |
2008-10-17 |
Lab Francais Du Fractionnement |
"composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
|
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
|
WO2008060780A2
(en)
|
2006-10-04 |
2008-05-22 |
Novo Nordisk A/S |
Glycerol linked pegylated sugars and glycopeptides
|
|
JP2010512306A
(ja)
*
|
2006-10-27 |
2010-04-22 |
ザ ロックフェラー ユニバーシティー |
抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
|
|
FI20075030A0
(fi)
*
|
2007-01-18 |
2007-01-18 |
Suomen Punainen Risti Veripalv |
Menetelmä solujen modifioimiseksi
|
|
EP2144923B1
(en)
|
2007-04-03 |
2013-02-13 |
BioGeneriX AG |
Methods of treatment using glycopegylated g-csf
|
|
KR101426667B1
(ko)
|
2007-04-17 |
2014-08-06 |
스티칭 디엔스트 랜드보위쿤디그 온데조에크 |
비-포유동물 글리코실트랜스퍼라제의 발현에 의한 식물에서의 포유동물형 글리코실화
|
|
AU2008245524A1
(en)
*
|
2007-04-26 |
2008-11-06 |
Cnj Holdings, Inc. |
Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
|
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
|
US7968811B2
(en)
*
|
2007-06-29 |
2011-06-28 |
Harley-Davidson Motor Company Group, Inc. |
Integrated ignition and key switch
|
|
US8546328B2
(en)
|
2007-08-27 |
2013-10-01 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
|
TWI488640B
(zh)
|
2008-04-16 |
2015-06-21 |
菲瑞茵國際中心股份有限公司 |
藥學製劑
|
|
EP2166085A1
(en)
|
2008-07-16 |
2010-03-24 |
Suomen Punainen Risti Veripalvelu |
Divalent modified cells
|
|
WO2010051227A1
(en)
|
2008-10-29 |
2010-05-06 |
Centocor Ortho Biotech Inc. |
Galactose alpha (1-3) galactose compositions
|
|
US9234192B2
(en)
|
2010-02-16 |
2016-01-12 |
Novo Nordisk A/S |
Conjugated proteins
|
|
IN2014CN02982A
(enExample)
|
2011-10-01 |
2015-07-03 |
Glytech Inc |
|
|
AU2013222414B2
(en)
|
2012-02-21 |
2018-02-15 |
Cytonics Corporation |
Systems, compositions, and methods for transplantation
|
|
WO2014018747A2
(en)
|
2012-07-26 |
2014-01-30 |
Momenta Pharmaceuticals, Inc. |
Glycoproteins with anti-inflammatory properties
|
|
AU2014245917B2
(en)
*
|
2013-03-29 |
2017-09-28 |
Glytech, Inc. |
Polypeptide having sialylated sugar chains attached thereto
|
|
ES2708759T3
(es)
|
2013-05-13 |
2019-04-11 |
Momenta Pharmaceuticals Inc |
Procedimientos para el tratamiento de la neurodegeneración
|
|
WO2015031654A2
(en)
|
2013-08-28 |
2015-03-05 |
Cytonics Corporation |
Systems, compositions, and methods for transplantation and treating conditions
|
|
EP3058084A4
(en)
|
2013-10-16 |
2017-07-05 |
Momenta Pharmaceuticals, Inc. |
Sialylated glycoproteins
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
US10889631B2
(en)
|
2014-11-20 |
2021-01-12 |
Cytonics Corporation |
Therapeutic variant alpha-2-macroglobulin compositions
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
CA2986625A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Methods for preparing modified von willebrand factor
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
WO2019043457A2
(en)
|
2017-09-04 |
2019-03-07 |
89Bio Ltd. |
CONJUGATES OF MUTANT PEPTIDE FGF-21 AND USES THEREOF
|
|
WO2020204814A1
(en)
*
|
2019-03-29 |
2020-10-08 |
Agency For Science, Technology And Research |
Method of sialylating a protein
|